- Home
- RCKT
as 07-26-2024 4:00pm EST
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 1.9B | IPO Year: | N/A |
| Target Price: | $52.78 | AVG Volume (30 days): | 887.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.85 | EPS Growth: | N/A |
| 52 Week Low/High: | $14.89 - $32.53 | Next Earning Date: | 08-08-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 488.18% |
Latest Rocket Pharmaceuticals Inc. News
RCKT Breaking Stock News: Dive into RCKT Ticker-Specific Updates for Smart Investing
MT Newswires
23 days ago
Canaccord Genuity Adjusts Price Target on Rocket Pharmaceuticals to $40 From $49, Maintains Buy Rating
Zacks
25 days ago
FDA Rejects Rocket's (RCKT) Gene Therapy BLA for Rare Disease
MT Newswires
a month ago
Needham Trims Price Target on Rocket Pharmaceuticals to $52 From $53, Maintains Buy Rating
MT Newswires
a month ago
Rocket Pharmaceuticals Says FDA Seeks More Information on Kresladi
Benzinga
a month ago
FDA Rejects Rocket Pharmaceuticals' Gene Therapy For Rare Immune Disorder, Asks For More Data, Stock Slides
BioPharma Dive
a month ago
Rocket gene therapy rejected by FDA over manufacturing
Business Wire
a month ago
Rocket Pharmaceuticals Provides Regulatory Update on KRESLADI™ (marnetegragene autotemcel; marne-cel)
Yahoo Finance Video
2 months ago
FDA panel votes to recommend Eli Lilly's Alzheimer's drug
Compare RCKT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RCKT Rocket Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.